Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
92 Results Found
CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model, BALANCE, for Medicare Part D and Medicaid beneficiaries.
CMS releases proposed rules on two drug pricing models
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.
Administration reaches deals with 9 drug companies to lower drug costs
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid by other developed nations.
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.
CMS Issues Proposed Rule for CY 2027 Medicare Advantage, Prescription Drug Plans
The Centers for Medicare & Medicaid Services (CMS) Nov. 28 released its proposed Policy and Technical Changes to the Medicare Advantage (MA) Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program and Programs of All-Inclusive Care for the Elderly for Contract Year (CY) 2027.
U.S. reaches trade agreement with U.K. on drug pricing
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In exchange, the U.K. will increase the net price it pays for new medicines by 25%.
CMS announces latest negotiated prices for 15 drugs to begin in 2027
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
Integrated CVS-Aetna: What’s at Stake
For the second time in less than a month, the Department of Justice has approved a megamerger between leading players in the health insurance and pharmacy worlds. The DOJ said it will allow the $69 billion merger of CVS Health with Aetna once the insurer sells its Medicare Part D business, which raised concerns about the companies having too much market control.
White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price.